Introduction
T-cell large granular lymphocyte (T-LGL) leukemia is a rare heterogeneous disorder that represents a distinct group of mature chronic T-cell neoplasias. Based on characteristic clinical, morphological, immunophenotypical and molecular features it was recognized as a separate clinical entity in the World Health Organization (WHO) classification. 1 Clonal LGL proliferations are assumed to be derived from normal LGL cells, which comprise 10-15% of peripheral blood (PB) MNC. 2 The diagnosis of T-LGL leukemia is based on the finding of an abnormal CD3
þ /CD57 þ cell population in combination with the presence of a clonal T-cell receptor (TCR) gene rearrangement. Clonal T-LGL proliferations usually express TCRab and show a CD8 þ þ /CD4 À phenotype, although some cases correspond to CD4 þ /CD8 À/ þ dim T-LGLs. 3 Other molecules expressed on cytotoxic cells, such as CD16, CD56, CD11b and CD11c are variably expressed. A minor subgroup of T-LGL leukemias expresses TCRgd; their CD4/CD8 immunophenotype is not well defined.
T-LGL leukemia patients may present with recurrent bacterial infections owing to (severe) neutropenia, anemia, and hepatosplenomegaly, but one-third of patients appear to be asymptomatic at diagnosis. [4] [5] [6] A strong association with different autoimmune diseases (in particular, rheumatoid arthritis) and hematological malignancies has been reported. 4, 5, 7 In all patients with unexplained cytopenias and high numbers of cytotoxic T-cells the diagnosis should be suspected and PB smears should be carefully examined for LGL cells.
LGLs have typical morphological characteristics such as abundant cytoplasm and coarse azurophilic granules. The diagnosis of T-LGL leukemia can however not be excluded if no increased numbers of LGLs are found by cytomorphology, because characteristic cytomorphological features may be absent. 5, 7, 8 Consequently, immunophenotyping is needed for an appropriate diagnosis.
It should be noted that not all T-LGL proliferations are clinically malignant. It has been suggested that T-LGL leukemia is at the end of a spectrum which ranges from a reactive/ transient indolent disorder, via chronic lymphocytosis to clinically malignant disease requiring intensive therapy. 5, [9] [10] [11] Chronic reactive proliferations of both TCRab þ and TCRgd þ T-LGL cells are seen in various clinical conditions. 4, 12 In these cases, lymphocytosis often is o5 Â 10 9 /l. In T-LGL leukemia the number of PB LGLs usually is 42 Â 10 9 /l, although lower LGL counts can be compatible with the diagnosis of leukemia as well. 5, 13 By definition, TCR genes are clonally rearranged in T-LGL leukemia, 14, 15 whereas in benign (reactive) proliferations polyclonal TCR gene rearrangements are found. Nevertheless, the finding of clonality certainly does not imply clinical malignancy, as most patients with clonal T-LGL proliferations have an indolent clinical course not requiring therapy.
The currently available clinical and laboratory data are mainly derived from patients with TCRab þ T-LGL leukemia, as TCRgd þ T-LGL lymphoproliferations are rare. True cases of TCRgd þ T-LGL leukemia have only been described anecdotally. [15] [16] [17] [18] [19] [20] [21] [22] We therefore aimed to assess the clinical features, immunophenotypical characteristics, and TCR gene rearrangement pattern of a large series of 44 TCRgd þ T-LGL leukemias in order to get more insight into the molecular pathogenesis of this disease. A major part of the cases showed Vg9/Vd2 expression with the typical antigen-selected characteristics as seen in antigen-selected TCRgd þ T lymphocytes of older children and adults. Consequently, antigenic stimulation might play a role in the pathogenesis of TCRgd þ T-LGL leukemia.
Materials and methods

Patients and cell samples
We retrospectively reviewed database files from the Erasmus MC, University Medical Center (Rotterdam, The Netherlands), the Hospital Universitario (Salamanca, Spain), and the Hospital Geral Santo Antó nio (Porto, Portugal) for cases of mature persistent TCRgd þ T-cell proliferations in PB and/or BM, between 1990 and 2005. Patient samples were classified according to a combination of clinical, laboratory, histological (HE sections), cytomorphological (May-Grü nwald-Giemsa staining), immunophenotypical and molecular data. In case of a confirmed hematological malignancy, the sample was classified according to the WHO classification of hematological malignancies. 1 This resulted in 53 TCRgd þ T-cell proliferations of which 44 fulfilled the diagnostic criteria of T-LGL leukemia. 8, 13 The diagnosis of TCRgd þ T-LGL leukemia was based on the finding of a persistent (46 months 
LGL proliferation in PB. Both cases with increased T-LGLs (42 Â 10 9 /l) or a discrete T-LGL expansion as detected by flow cytometry and/or cytomorphology were included. The other diagnoses concerned persistent reactive TCRgd In all TCRgd þ T-LGL leukemia cases, the molecular and immunophenotypical analyses were performed on PB and/or BM samples. Either erythrocyte-lysed samples (using FACSt lysing solution; BD Biosciences, San Jose, CA) or PB/BM MNC isolated by Ficoll-Paque (density: 1.077 g/ml; Pharmacia, Uppsala, Sweden) density centrifugation were used for immunophenotyping and DNA isolation. Cytomorphological MayGrü nwald-Giemsa staining of PB smears was used for detection of LGLs. In 36 patients, the BM was also examined at diagnosis. In all 36 cases this was done on bone marrow smears, while in eight of these cases trephine biopsies were also examined.
As controls, neonatal cord blood (NCB) samples and PB samples from children and adults were analyzed after informed consent was given by them or their parents. All patient and control samples were obtained according to the guidelines of the Medical Ethics Committee of Erasmus MC, Rotterdam.
Immunophenotyping and analysis of Vg and Vd domains of expressed TCR chains
Cells were analyzed for cell membrane expression of T-and NKcell associated antigens, including CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD56, CD57, and HLA-DR antigens, and for TCRab (BMA031 and WT31) or TCRgd (11F2) expression. In about half of cases expression of the adhesion molecules CD11b and CD11c was studied. Immunofluorescence stainings were performed as described 3, 23 and evaluated on either FACScan or þ /TCRgd þ T lymphocytes. Part of these results have been described previously. 24 We also analyzed the expression of Vg9 (Ti-gA), Vd1 (dTCS1), and Vd2 (BB3) by TCRgd þ T lymphocytes in NCB samples (n ¼ 10) and PB samples from healthy children (three different age groups; n ¼ 15) and adults (n ¼ 15).
DNA isolation
High molecular weight DNA from fresh or frozen MNC was either extracted using a phenol-chloroform extraction-based protocol, followed by ethanol precipitation and resolution in TE buffer, 25 or isolated using the GenElute Mammalian Genomic DNA miniprep kit (Sigma-Aldrich, St Louis, MO) according to the manufacturer's protocol.
TCR gene rearrangement analysis
Amplification reactions were performed in an automated thermocycler (model ABI 9600/2700; Applied Biosystems, Foster City, CA, USA) according to the BIOMED-2 multiplex PCR protocol. 26 In order to amplify the most commonly recognized canonical TCRG gene rearrangement that involves the Vg9 and Jg1.2 gene segments, we performed an additional singleplex PCR reaction using BIOMED-2 Vg9 and BIOMED-1 Jg1.2 primers. All BIOMED-2 multiplex PCR kits were obtained from InVivoScribe Technologies (San Diego, CA, USA; www. invivoscribe.com). After PCR amplification of TCRG and TCRD gene rearrangements, products were subjected to both heteroduplex (HD) and GeneScan (GS) analysis for identification of monoclonal gene rearrangements. 27, 28 Sequence analysis PCR products found to be monoclonal in HD and GS analysis were directly sequenced except for cases with more than one clonal product. In such cases, homoduplexes were excised from the polyacrylamide gel, eluted, and directly sequenced. 29 Sequencing was performed either on the ABI377 fluorescent sequencer (Applied Biosystems), using the dye terminator cycle sequencing kit and AmpliTaqFS DNA polymerase (Applied Biosystems), as previously described 30 or on an ABI 3100 Genetic Analyzer. Assignment of Vg, Jg, Vd, Dd, and Jd gene segments and reading frames of the involved TCRG and TCRD gene rearrangements was done using the IMGT database. Table 1 summarizes the most relevant clinical and hematological findings at diagnosis of the 44 TCRgd þ T-LGL leukemia patients enrolled in this study. The median age was 63 years (range 34-88) and there was no male or female predominance. Twenty-seven patients (61%) were symptomatic at presentation. T-LGL leukemia cases frequently (48%) presented with neutropenia. Also some T-LGL leukemias presented with multiple cytopenias, including anemia in eleven (23%), thrombocyto- Neutropenia was defined as absolute neutrophil count (ANC) less than 1.5 Â 10 9 neutrophils/l. Anemia was defined as hemoglobin level o10 g/dl. Thrombocytopenia was defined as platelet count o150 Â 10 9 /l. AIHA, autoimmune hemolytic anemia; AITD, autoimmune thyroiditis; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; B-ALL, B-cell acute lymphoblastic leukemia; B-CLL, B-cell chronic lymphocytic leukemia; CSA, cyclosporine A; MGUS, monoclonal gammopathy of undetermined significance; MTX, methotrexate; PRCA ,pure red cell aplasia; RA, rheumatoid arthritis; RBC, red blood cell; SMZL, splenic marginal zone lymphoma.
Results
Clinical and laboratory features of TCRgd þ T-LGL leukemia
penia in four (9%), and pancytopenia in one (2%). Fatigue and B symptoms (fever, night sweats, weight loss) were present in five patients (11%) and recurrent infections occurred in five cases as well (11%). Splenomegaly and hepatomegaly were found in 18% and 7% of cases, respectively.
An associated disease was found in 23 cases (52%) ( Table 1 ). In our series, 15 patients (34%) had a coexistent autoimmune disorder. The most common autoimmune manifestation was rheumatoid arthritis (RA), which was diagnosed in seven patients (16%). Coexistence of a second hematological malignancy was demonstrated in six patients (14%).
Examination of PB smears showed an increased number of T-LGLs with abundant cytoplasm containing azurophilic granules (Figure 1a ) in 25 out of 44 cases (57%), similar to normal TCRgd þ T-cells (Figure 1b) . In the remaining 19 cases, we found evidence for the presence of a discrete LGL expansion with low LGL counts ( Table 1) . Cytomorphological BM examination demonstrated LGL infiltration in 29 out of 36 cases (81%). Histopathological analysis of BM biopsies in HE sections demonstrated lymphocytic infiltration in eight evaluable patients.
All patients tested (n ¼ 22) were seronegative for hepatitis B surface antigen (HBs Ag) and anti-hepatitis C antibody (HCV Ab). We did not detect EBV or CMV DNA sequences in PB MNC DNA in the 30 patients tested.
Therapy and follow-up of TCRgd þ T-LGL leukemia Table 1 shows the different therapeutical strategies in the individual patients. In 21 cases, the clinical course was indolent and no therapy was required, while another 18 patients were treated with one or more different approaches. The therapeutic strategy was largely aimed at improving cytopenias and included granulocyte-colony stimulating factor, erythropoietin, red blood cell transfusions, variable immunosuppressive agents, purine analogs, alemtuzumab, and polychemotherapy with alkylating agents. From the remaining five patients no therapeutical data were available. We observed no disease-related deaths in 18 patients followed for at least 3 years, which is consistent with an indolent clinical course. From the remaining patients no longterm clinical follow-up data were available.
Immunophenotypical characteristics of TCRgd þ T-LGL leukemia
In all cases, the LGLs coexpressed the TCRgd and CD3 molecules on the cell surface in the absence of TCRab expression. These cells predominantly showed a CD4 À /CD8 þ immunophenotype (66% of cases), whereas the remaining cases were CD4 À /CD8 À (34%). Variable expression was seen for CD16 (45%), CD56 (45%), while CD57 was expressed in 37 out of 43 patients (86%) ( Table 1) . Coexpression of CD56 and CD57 was seen in 43% of patients, while 41% of cases showed the CD16/CD57 immunophenotype. The vast majority of leukemic
LGLs expressed CD2 (100%), CD5 (86%), CD7 (93%), and CD11c (83%). Heterogeneous expression was seen for HLA-DR (64%) and CD11b (58%) among the cases tested.
Immunophenotypical and molecular Vg/Vd analysis of TCRgd þ T-LGL leukemia
The TCR repertoire was studied using specific anti-TCR Vg/Vd domain MoAbs in 38 out of 44 patients, with a dominant TCR Vg/Vd combination being expressed in each case. Monoclonal TCR gene rearrangements could be found in all 44 patient samples, as detected by both PCR based HD and GS analysis. Detailed information concerning the TCR Vg/Vd expression and configuration of TCRG and TCRD genes of each TCRgd þ T-LGL leukemia is summarized in Table 2 . Results of sequence analysis of TCRG and TCRD gene rearrangements and Vg/Vd protein expression was concordant in 33 cases. In case no. 24 and 44 clonal out-of-frame TCRG gene rearrangements were found and no DNA was left for further TCRG and TCRD gene rearrangement analysis. In the remaining nine cases, no or incomplete flowcytometric analysis of Vg/Vd chains was performed.
Combined molecular and immunophenotypical data demonstrated the Vg9/Vd2 phenotype to be present in 21 out of 44 cases (48%), whereas 15 cases (34%) were positive for Vd1 in combination with Vg other than Vg9. In four patients (9%), a Vg9/Vd1 immunogenotype was detected. The four remaining cases demonstrated expression of Vg9/Vd3, Vg2/Vd3, Vg5/Vd2, and Vg3/Vd2. The predominant expression of Vg9 (n ¼ 26; 59%), Vd2 (n ¼ 23; 52%) and Vd1 (n ¼ 19; 43%) in TCRgd 
Detailed comparison of normal TCRgd þ T-lymphocytes and TCRgd þ T-LGL leukemias
To gain further insight into the pathogenesis of TCRgd þ T-LGL leukemias we compared normal TCRgd þ T-cells and TCRgd þ T-LGL leukemias in more detail. We evaluated the absolute size of the CD3 þ and the CD3 þ /TCRgd þ lymphocyte subpopulations in NCB and PB from healthy individuals of different age groups (Figure 2) . The absolute number of T lymphocytes increases immediately after birth, remains relatively stable until 2 years of age, and subsequently decreases threefold to adult levels ( Figure 2a) . A fivefold increase of absolute numbers of TCRgd þ T lymphocytes occurs during the first 2 years of life, followed by a gradual decrease to adult levels (Figure 2b ). In NCB, approximately half of the TCRgd þ T lymphocytes expressed Vd1, while 30-40% expressed Vg9 and/or Vd2 (Figure 2c ). However, during early childhood the distribution of Vg and Vd gene usage changes to 10-15% Vd1, 80-85% Vd2, and 85-90% Vg9 in older children and adults (Figure 2c) .
GeneScan patterns of the most frequently used TCRG (Vg9-Jg1.2) and TCRD (Vd2-Jd1 and Vd1-Jd1) gene rearrangements in both immature and mature TCRgd þ T-cells are illustrated in Figure 3 . A polyclonal GS pattern can be found in normal TCRgd þ thymocytes and MNC. Oligoclonal gene rearrangements are detected in a persistent reactive TCRgd þ lymphoproliferation, while clear monoclonal peaks are present in PB samples from TCRgd þ T-LGL leukemia patients. (Figure 4 ). This first codon encoded leucine (50%), valine (32%) or isoleucine (19%) ( Table 3 ). The invariant T nucleotide is a peripheral antigen selection marker that is absent in DNA isolated from thymocytes and cord blood MNC but is present in DNA from normal adult PB MNC (Figure 4) . 32 As no similar marker is known for Vd1 junctions, further evaluation of the Vd1 phenotype for signs of antigen selection was not possible. Taken together our data show that TCRgd þ T-LGL leukemias are quite similar to normal PB TCRgd þ T-cells in Vg/Vd usage and the presence of the Vd2 selection determinant, and differ in their CD4/CD8 pattern.
Discussion
TCRgd
þ T-Lgl leukemias form a rare subgroup of mature T-cell malignancies, representing approximately 5% of CD3 þ T-LGL LGL leukemia, 7, 20 but data on large series are lacking. Here we describe the clinical presentation and laboratory parameters of an unprecedentedly large group of newly diagnosed patients with TCRgd þ T-LGL leukemia. The most prominent clinical manifestations of the disease consisted of cytopenias and to a lesser extent the presence of splenomegaly and frequent association with autoimmune diseases and other neoplasms, as previously described for TCRab þ T-LGL leukemia. [3] [4] [5] [6] 33 Similar to TCRab þ cases, most TCRgd þ T-LGL leukemias have an indolent clinical course and do not require management with cytotoxic drugs. As eradication of the malignant clone does not seem to be essential for disease control, effective immunomodulatory agents such as methotrexate and cyclosporine seem to be preferred over intensive cytotoxic regimens. [34] [35] [36] [37] However, results of future international standardized treatment protocols should reveal the optimal therapeutic strategy for both TCRab þ and TCRgd þ T-LGL leukemias. In the majority of T-LGL leukemia cases, the leukemic LGLs express CD3, CD8 and TCRab. With regard to TCRgd þ cases, both CD4
À /CD8 þ and CD4 À /CD8 À phenotypes have been described. 19, 21, 38 In contrast to the CD4 À /CD8 À immunophenotype of most normal TCRgd þ T-lymphocytes in PB as well as TCRgd þ thymocytes, TCRgd þ T-ALL, and TCRgd þ HSTCL, the TCRgd þ T-LGL leukemias in our study were predominantly CD8 þ (n ¼ 29; 66%) ( Table 3) , demonstrating the activated memory immunophenotype 3, 39 of most leukemic TCRgd þ T-LGL proliferations. The most common immunophenotype of T-LGL leukemias (CD3 þ /CD8 þ /CD57 þ ) 6 was found in 25 out of 44 patients (57%), and CD57 expression was observed in nearly 90% of cases. The CD3 þ /CD56 þ phenotype with variable expression of CD16 and CD57 was found in 45% of cases in our series. In contrast to the report by Gentile et al., 40 the clinical presentation and disease course of our patients showing a CD56 þ phenotype was similar to that of the other patients, none of them suffering from severe illness. þ T lymphocytes in neonatal cord blood, blood from healthy children (eight different age groups) and blood from healthy adults. 24 (b) Absolute number of TCRgd þ T lymphocytes in neonatal cord blood, blood from healthy children (eight different age groups) and blood from healthy adults. (c) Vg and Vd usage by TCRgd þ T lymphocytes in neonatal cord blood, blood from healthy children (three different age groups) and blood from healthy adults. The expression of Vg9 (Ti-gA), Vd1 (dTCS1), and Vd2 (BB3) was assessed within the TCRgd þ T-cell population, defined as CD3 þ / TCRab Figure 4 Invariant T nucleotide in the first codon of the Vd2-Jd1 junctional region. The invariant T nucleotide is absent in Vd2-Jd1 junctional regions of neonatal cord blood MNC, but is present in polyclonal PB MNC of healthy adults. In all 16 analyzed Vd2-Jd1 junctional regions of clonal Vg9 þ /Vd2 þ T-LGL leukemias, the invariant T nucleotide could be detected as well. 
It has been hypothesized that antigen-driven T-cell expansions are the first phase in the pathogenesis of T-LGL leukemia. [41] [42] [43] Additional (genetic) events might then transform the abnormal polyclonal or oligoclonal expansion into a monoclonal proliferation. [44] [45] [46] The antigen nature and specificity of T-LGL clones remains unknown. Some cases of T-LGL leukemia occur concomitantly with viral infections, such as EBV, CMV, HIV, HTLV, and HCV. 4, 47 However, we found no evidence for a potential relationship between active viral infections and TCRgd þ T-LGL leukemia. Owing to the extensive combinatorial repertoire of TCRab molecules, it is complicated to define antigen-selection via analysis of TCR molecules in TCRab þ T-LGL leukemias. This is in contrast to TCRgd molecules, which show a restricted combinatorial repertoire and thereby allow better insight in antigen-selection of TCRgd þ T-cells. In thymus and NCB, TCRgd þ T-cells mainly express Vd1 chains. 48, 49 However, during the expansion of TCRgd þ T-cells during the first 2 years of life, the Vd1 usage shifts to Vg9/Vd2 usage ( Figure 2) . Importantly, we have previously demonstrated that this thymus-independent peripheral expansion of TCRgd þ T-cells is accompanied by selection for an invariant T nucleotide in the first codon of the Vd2-Jd1 junctional region. 32 Consequently, the expanded Vg9 þ /Vd2 þ T lymphocytes are antigenselected. Apparently these T lymphocytes have proliferated in response to a ubiquitous antigen or microorganism, which has not yet been identified, for example, a (super)antigen. The antigen-selected and activated state of the T-LGLs is further supported by the expression of the activated memory T-cell marker CD8 in the majority of cases. Nevertheless, at this point we cannot completely exclude the possibility that LGL proliferations result from secondary oncogenic events in randomly selected TCRgd þ T-cells. This needs to be further addressed in future studies.
In our series of adult TCRgd þ T-LGL leukemia patients, nearly half showed the Vg9/Vd2 phenotype. The Vg9-Jg1.2-Cg1 and Vd2-Jd1-Cd immunogenotype could be confirmed in 16 cases. In all 16 patients, the antigen-selected invariant T nucleotide could be identified in the first codon of the Vd2-Jd1 junctional region. Expression of Vd1 was found in another 19 cases. The preferential expression of the antigen-selected Vg9/Vd2 phenotype and the frequent usage of the Vd1 subunit seem to reflect the spectrum of normal TCRgd þ T-cells in PB of healthy adult individuals ( Figure 2c and Table 3 ). This contrasts with the Vg/ Vd usage of normal TCRgd þ thymocytes, TCRgd þ T-ALL, and TCRgd þ HSTCL where Vd1 usage predominates (Table 3) . Although no clear clinical features such as autoimmune phenomena seem to correlate with certain Vg/Vd usage, it is interesting to note that all three T-LGL leukemia patients with pure red cell aplasia (PRCA) express the Vd1 chain. This phenotype has been described previously in a case of TCRgd þ T-LGL leukemia and PRCA. 
